IT1156739B - Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects - Google Patents

Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects

Info

Publication number
IT1156739B
IT1156739B IT4935378A IT4935378A IT1156739B IT 1156739 B IT1156739 B IT 1156739B IT 4935378 A IT4935378 A IT 4935378A IT 4935378 A IT4935378 A IT 4935378A IT 1156739 B IT1156739 B IT 1156739B
Authority
IT
Italy
Prior art keywords
carnitine
compsn
hyperlipaemia
hypercholesterolaemia
racemate
Prior art date
Application number
IT4935378A
Other languages
Italian (it)
Other versions
IT7849353A0 (en
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT4935378A priority Critical patent/IT1156739B/en
Publication of IT7849353A0 publication Critical patent/IT7849353A0/en
Priority to DE2903558A priority patent/DE2903558C2/en
Priority to GB7903649A priority patent/GB2013495A/en
Priority to CH106279A priority patent/CH640414A5/en
Priority to NL7900871A priority patent/NL7900871A/en
Priority to JP1171679A priority patent/JPS54113409A/en
Priority to US06/083,418 priority patent/US4255449A/en
Application granted granted Critical
Publication of IT1156739B publication Critical patent/IT1156739B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compsns. contain D,L-carnitine, D-carnitine, L-carnitine or their salts, esters or amides in an effective quantity to reestablish normal metabolism and a pharmaceutical vehicle or support. Unlike known compsns. the present compsn. is free from undesirable side-effects. The compsns. are administered orally or parenterally in daily doses of 10-50 mg/kg of active cpd. Animal tests and clinical trials are described.
IT4935378A 1978-02-03 1978-05-15 Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects IT1156739B (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IT4935378A IT1156739B (en) 1978-05-15 1978-05-15 Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects
DE2903558A DE2903558C2 (en) 1978-02-03 1979-01-31 Use of L-carnitine
GB7903649A GB2013495A (en) 1978-02-03 1979-02-02 Therapeutic method for the treatment of hyperlipodaemias and hyperlipoproteinaemias
CH106279A CH640414A5 (en) 1978-02-03 1979-02-02 THERAPEUTIC PREPARATION FOR THE TREATMENT OF HYPERLIPOPROTEINEMIE, DYSLIPEMIA AND RELATED DISEASES.
NL7900871A NL7900871A (en) 1978-02-03 1979-02-02 PROCEDURE FOR THE THERAPEUTIC TREATMENT OF HYPERLIPIDEMIA AND HYPERLIPI PROTEINEMIA.
JP1171679A JPS54113409A (en) 1978-02-03 1979-02-03 Treating agent for hyperlipoid disease
US06/083,418 US4255449A (en) 1978-02-03 1979-10-10 Method of treating abnormal lipoprote in ratios

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT4935378A IT1156739B (en) 1978-05-15 1978-05-15 Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects

Publications (2)

Publication Number Publication Date
IT7849353A0 IT7849353A0 (en) 1978-05-15
IT1156739B true IT1156739B (en) 1987-02-04

Family

ID=11270444

Family Applications (1)

Application Number Title Priority Date Filing Date
IT4935378A IT1156739B (en) 1978-02-03 1978-05-15 Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects

Country Status (1)

Country Link
IT (1) IT1156739B (en)

Also Published As

Publication number Publication date
IT7849353A0 (en) 1978-05-15

Similar Documents

Publication Publication Date Title
CA2191645A1 (en) Pharmaceutical composition comprising l-carnitine or an alkanoyl l-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders
CA2257121A1 (en) Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
FI973163A0 (en) Treatment of incontinence using (S) -oxybutynin and (S) -desethyloxybutynin
PT64840A (en) PROCESS FOR THE PREPARATION OF ARALQUILIC ESTERS OF 1,4-DIHYDRAPIRIDINOCARBOXILIC ACID WITH CORONARY AND ANTIHYPERTENSIVE EFFECT APPLICATION OF THE SAME FOR THE PREPARATION OF CORONARY AND ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITIONS AND APPLICATION OF SAID PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BLOOD LACIRCULATION DISEASES
PT825858E (en) DEPENDENT TIME-RELEASING CAPSULES CONTAINING POLYINSATURATED ACIDS OMEGA-3 FOR THE TREATMENT OF INFLAMMATORY DISEASE OF THE INTESTINE
KR920000324A (en) Essential Fatty Acid Treatment
KR900700089A (en) Pharmaceutical Compositions for Systemic Skin Permeable Administration
KR840003414A (en) Pharmaceutical compositions containing 3-hydroxybutanoic acid or salts derived from these acids, and compounds derived from 3-hydroxybutanoic acid that can be used as pharmaceuticals
PT83474B (en) A process for the preparation of a pharmaceutical composition comprising 2- (2-fluoro-4-biphenyl) propionic acid or a pharmaceutically acceptable salt thereof
TW197423B (en)
FR2437834A1 (en) L-serine or glycine for treatment of cerebral deficiencies - such as mongolism and general mental debility, etc.
FR2618331B1 (en) PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF UREMIA
ES2125215T3 (en) PROCEDURE FOR THE PREPARATION OF A DELAY PRODUCT CONTAINING DILTIAZEM FOR A SINGLE DAILY ADMINISTRATION.
ES2078019T3 (en) L-CARNITINE ALCANOYL AMIDES WITH AMINO ACIDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM TO PROMOTE REGENERATION OF THE NERVOUS TISSUE, INHIBIT NEURONAL DEGENERATION, IMPROVE THE PROCESS OF LEARNING AND MEMORY AND FOR THE TREATMENT OF COMA.
IT1104165B (en) Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects
IT1156739B (en) Carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and associated lipid metabolism defects
EP0302481A3 (en) Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
JPS57126420A (en) Drug for digestive organ
ATE98486T1 (en) SELF-ADHESIVE DEVICE FOR TRANSDERMAL DELIVERY OF A DRUG.
IL37640A (en) Pharmaceutical and veterinary compositions containing an amino carboxylic acid derivative
ES8205394A1 (en) Treatment of shock
KR890000399A (en) (E) -2- (P-fluorophenethyl) -3-fluoroallylamine
ATE212840T1 (en) SOLID MEDICINAL PREPARATIONS FOR ORAL APPLICATION WITH MODULATED RELEASE OF ACTIVE INGREDIENTS CONTAINING NICORANDIL AND METHOD FOR THE PRODUCTION THEREOF
KR980700083A (en) Kit for Osteoporosis Treatment Cycle
IT1156740B (en) Acyl carnitine compsn. as the racemate or optical isomers - is used to treat hyperlipaemia, hypercholesterolaemia and other lipid metabolism defects

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970416